European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new anti-VEGF therapy. Read more
Warby Parker launches its own contact lens
US-based online retailer of prescription spectacles Warby Parker has entered a new section of the ophthalmic market with its own brand of contact lenses. Read more
Ocular gene therapy begins on the NHS
The UK’s national health provider has started treating patients with Leber’s Congenital Amaurosis (LCA) with a new sight-restoring gene therapy. Read more
US approves first ever treatment for thyroid eye disease
Horizon Therapeutics has had its drug Tepezza, which is the first ever treatment for thyroid eye disease, approved by The US Food and Drug Administration (FDA). Read more
Patient receives first wireless retinal device implant
A surgeon at the University of Pittsburgh Medical Center (UPMC) has implanted the first patient in the US with a new wireless retinal device. Read more
Commission probes proposed EssilorLuxottica-GrandVision acquisition
EssilorLuxottica has reaffirmed its goal to complete the acquisition of optical retail giant GrandVision within the next 18 months following the announcement of a new investigation by the European competition watchdog. Read more
Chinese ophthalmologist and coronavirus whistle-blower dies
An ophthalmologist who Chinese authorities attempted to silence during the initial stages of the coronavirus outbreak has died after contracting the disease himself from a glaucoma patient. Read more
Treatment for CSCR found to have “no benefit”
New research from the University of Bristol and University Hospital Southampton has concluded that eplerenone offers no benefit for patients suffering from central serous chorioretinopathy (CSCR), and subsequently should no longer be prescribed for the condition. Read more
Poor vision as detrimental to learning as poverty
New research from the World Bank and international charity organisation EYElliance has found that an unaddressed vision problem can be just as detrimental to a child’s learning as socio-economic disadvantage. Read more
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors. Read more